$29.56
1.69% today
Nasdaq, Dec 04, 10:00 pm CET
ISIN
US1523091007
Symbol
CNTA

Centessa Pharmaceuticals plc - ADR Stock price

$29.07
+5.13 21.43% 1M
+15.71 117.59% 6M
+12.32 73.55% YTD
+11.95 69.80% 1Y
+25.14 639.69% 3Y
+7.32 33.66% 5Y
+7.32 33.66% 10Y
+7.32 33.66% 20Y
Nasdaq, Closing price Wed, Dec 03 2025
+0.56 1.96%
ISIN
US1523091007
Symbol
CNTA
Industry

Key metrics

Basic
Market capitalization
$3.8b
Enterprise Value
$3.7b
Net debt
positive
Cash
$246.2m
Shares outstanding
134.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
255.5 | 227.5
EV/Sales
246.4 | 219.4
EV/FCF
negative
P/B
12.7
Financial Health
Equity Ratio
69.6%
Return on Equity
-58.7%
ROCE
-59.1%
ROIC
-130.0%
Debt/Equity
0.4
Financials (TTM | estimate)
Revenue
$15.0m | $16.8m
EBITDA
$-247.0m | $-214.1m
EBIT
$-247.9m | $-201.4m
Net Income
$-242.7m | $-187.3m
Free Cash Flow
$-181.4m
Growth (TTM | estimate)
Revenue
119.0% | -
EBITDA
-54.1% | -7.0%
EBIT
-53.7% | -0.2%
Net Income
-49.9% | 20.6%
Free Cash Flow
-39.4%
Margin (TTM | estimate)
Gross
-
EBITDA
-1,646.6% | -1,270.8%
EBIT
-1,652.7%
Net
-1,618.0% | -1,111.8%
Free Cash Flow
-1,209.5%
More
EPS
$-1.8
FCF per Share
$-1.3
Short interest
4.6%
Employees
98
Rev per Employee
$0.0
Show more

Is Centessa Pharmaceuticals plc - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Centessa Pharmaceuticals plc - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Centessa Pharmaceuticals plc - ADR forecast:

20x Buy
95%
1x Hold
5%

Analyst Opinions

21 Analysts have issued a Centessa Pharmaceuticals plc - ADR forecast:

Buy
95%
Hold
5%

Financial data from Centessa Pharmaceuticals plc - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
15 15
119% 119%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 50 50
1% 1%
335%
- Research and Development Expense 179 179
50% 50%
1,191%
-247 -247
54% 54%
-1,647%
- Depreciation and Amortization 0.91 0.91
5% 5%
6%
EBIT (Operating Income) EBIT -248 -248
54% 54%
-1,653%
Net Profit -243 -243
50% 50%
-1,618%

In millions USD.

Don't miss a Thing! We will send you all news about Centessa Pharmaceuticals plc - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Centessa Pharmaceuticals plc - ADR Stock News

Neutral
The Motley Fool
5 days ago
San Francisco-based 5AM Venture Management sold 150,000 CNTA shares in the third quarter. Despite the sale, the stock's sharp rally last quarter led the fund's net position value in CNTA to increase by $5.6 million.
Positive
The Motley Fool
17 days ago
California-based TCG Crossover Management increased its stake in Centessa Pharmaceuticals by 245,664 shares in the third quarter for an estimated $38.1 million. The transaction value equaled about 0.2% of the fund's 13F reportable assets under management (AUM) at quarter-end.
Positive
The Motley Fool
22 days ago
It's gearing up to take in a flood of fresh capital. This is being effected in a secondary issue of its ADSes.
More Centessa Pharmaceuticals plc - ADR News

Company Profile

Centessa Pharmaceuticals Ltd. operates as pharmaceutical company that develops medicines. The company was founded on October 26, 2020 and is headquartered in Cambridge, the United Kingdom.

Head office United Kingdom
CEO Saurabh Saha
Employees 98
Founded 2013
Website www.centessa.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today